Accretion Pharmaceuticals Share Price Today

Accretion Pharmaceuticals schedules investor meets in Mumbai

Accretion Pharmaceuticals Limited will hold investor and analyst meetings in Mumbai on June 26, 2026. The agenda features one-on-one meetings with I-Thought PMS and Divitae Investments, and a group meeting with Equilion, Arihant Capital, and HNI. The company stated that no unpublished price sensitive information will be shared during these discussions.

Accretion Pharmaceuticals promoters report no share encumbrance in FY26

Promoters of Accretion Pharmaceuticals Limited declared no shares were encumbered in FY26. The disclosure was filed with NSE under SEBI takeover regulations on April 7, 2026.

Accretion Pharma FY26 Net Profit Rises 42.3% to ₹9.67 Cr

Accretion Pharmaceuticals Limited announced audited FY26 results, reporting a 56.21% YoY increase in total income from operations to ₹89.63 crore and a 42.30% rise in net profit to ₹9.67 crore. While EBITDA grew 25.85% to ₹14.95 crore, margins faced pressure due to higher input and IPO-related costs. H2 FY26 revenue stood at ₹45.89 crore, with exports contributing 7.98%.

Accretion Pharmaceuticals Submits Structured Digital Database Compliance Certificate for FY Ended 31st March, 2026

Accretion Pharmaceuticals Limited submitted its Structured Digital Database Compliance Certificate to the National Stock Exchange of India Limited for the financial year ended 31st March, 2026. The certificate, issued by M/s. Sakhiya & Co., Practicing Company Secretaries, confirms adherence to Regulation 3(5) and 3(6) of SEBI (Prohibition of Insider Trading) Regulations, 2015. The company successfully captured 2 required events during the quarter, with no non-compliance observed and no remedial actions necessary.